DUPIXENT Drug Profile

Summary for Tradename: DUPIXENT

High Confidence Patents:	8
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for DUPIXENT
Recent Clinical Trials:	See clinical trials for DUPIXENT

See drug prices for DUPIXENT

Recent Clinical Trials for DUPIXENT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Gan & Lee Pharmaceuticals.	PHASE1
Parexel	PHASE1
Chong Kun Dang Pharmaceutical	PHASE1

See all DUPIXENT clinical trials

Pharmacology for DUPIXENT

Mechanism of Action	Interleukin 4 Receptor alpha Antagonists
Established Pharmacologic Class	Interleukin-4 Receptor alpha Antagonist
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for DUPIXENT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for DUPIXENT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	11,167,004		DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	11,345,712		DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	7,608,693		DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	8,075,887		DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	8,337,839		DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	8,945,559		DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	9,290,574		DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for DUPIXENT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	10,028,940	2037-03-16	Patent claims search
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	10,059,771	2034-06-20	Patent claims search
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	10,066,017	2035-11-13	Patent claims search
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	10,137,193	2035-02-20	Patent claims search
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	10,195,183	2037-08-14	Patent claims search
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	10,314,904	2037-02-17	Patent claims search
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	10,369,114	2037-05-24	Patent claims search

Market Dynamics and Financial Trajectory for DUPIXENT (dupilumab)

Last updated: February 19, 2026

What is the current market size and growth trajectory for DUPIXENT?

DUPIXENT, developed by Regeneron Pharmaceuticals and Sanofi, is a monoclonal antibody targeting IL-4 and IL-13 pathways. It primarily treats atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis. The drug's global sales reached $7.72 billion in 2022, marking a compound annual growth rate (CAGR) of ~58% from 2020 ($3.08 billion).

The company projects sales exceeding $11 billion by 2025. Market expansion hinges on approvals across additional indications and wider geographic reach.

How does DUPIXENT's market penetration compare across indications and regions?

Indication	Sales (2022)	Growth Rate (2020-2022)	Key Markets
Atopic dermatitis	$4.87B	55%	US, Europe, Japan
Asthma	$1.89B	62%	US, Europe
Nasal polyps	$0.78B	100% early growth	US, Europe
Eosinophilic esophagitis	Rolling out	Data not visible	US, UK

The U.S. remains the dominant revenue driver, representing approximately 60% of sales. Europe accounts for 25%, with Japan and other markets making up the remainder.

What are the primary competitive and patent considerations?

DUPIXENT's main competitors include:

• Adalimumab (Humira): Indications overlapping in eczema, but with a broader autoimmune profile.
• Lebrikizumab: Under development by Lilly, focusing on IL-13.
• Tralokinumab: Approved for atopic dermatitis in Europe and Japan.

Regeneron and Sanofi hold patents expiring between 2027 and 2032 in key jurisdictions. Competition from biosimilars may emerge post-expiry, potentially impacting revenue streams.

How are regulatory and pipeline developments influencing the outlook?

Regulatory agencies have approved DUPIXENT for:

• Moderate to severe atopic dermatitis (2017, US & EU)
• Severe asthma (2018, US & EU)
• Chronic rhinosinusitis with nasal polyposis (2019, US & EU)
• Eosinophilic esophagitis (2023, US)

Pipeline includes additional indications like chronic obstructive pulmonary disease (COPD) and food allergies, which could diversify revenue sources if approved.

What role do pricing strategies and reimbursement policies play?

Pricing in the US averages $37,000/year per patient. Insurers often require prior authorization, which can limit access. Reimbursement negotiations impact uptake, especially in countries with centralized healthcare systems. Price adjustments and expanded formulary inclusion can drive growth.

What are the financial risks associated with DUPIXENT?

Risks include:

• Patent expirations in key markets within next 5 years.
• Potential biosimilar entry impacting market share.
• Competitive advances by new biologics.
• Pending regulatory approvals for additional indications, where delays could affect revenue forecasts.

How does the overall R&D investment and pipeline affect long-term outlook?

Regeneron and Sanofi consistently invest $0.8-$1.2 billion annually in R&D. The pipeline includes candidate biologics targeting other cytokines and immune pathways. Success in expanding indications can sustain or elevate revenue.

Summary table of key financial metrics (2022-2025 projections):

Year	Revenue (USD billion)	% Growth	Predicted Market Share	Key Risks
2022	7.72	-	Dominant in atopic dermatitis	Patent expiry threats, biosimilar emergence
2023	9.50	23%	Increased asthma and EoE sales	Regulatory delays in new indications
2024	10.5	10.5%	Market expansion continues	Competitive pressure
2025	11+	~5-10%	Potential new indications	Market saturation in core indications

Key takeaways

• DUPIXENT dominates in atopic dermatitis and asthma, with high growth rates primarily from US markets.
• Patent expiries approaching in 2027-2032 could erode revenues unless extended patents or new indications materialize.
• The pipeline’s success, especially for EoE and other indications, will be critical for sustaining growth.
• Competition and biosimilar entry pose significant risk post-patent expiration.
• Pricing, reimbursement, and regulatory factors influence adoption rates and revenue scalability.

FAQs

Q1: What is the likelihood of DUPIXENT maintaining market leadership through 2030?
It depends on pipeline success, patent protection duration, and competitive landscape. Continued indication approvals and market expansion are essential.

Q2: How vulnerable is DUPIXENT to biosimilar competition?
Entry is expected post-2027 in key markets. Patent cliff alternatives include new patents, label extensions, or indications.

Q3: Which markets offer the highest growth potential?
Emerging markets in Asia-Pacific and indications like eosinophilic esophagitis could drive future growth.

Q4: Are there upcoming regulatory decisions that could impact revenue?
Yes, approvals for additional indications such as COPD are pending; delays could affect projections.

Q5: How does pricing compare internationally?
Pricing varies; US prices average at $37,000/year, whereas European prices tend to be lower due to healthcare system negotiations, affecting profitability margins.

---

References

[1] Regeneron Pharmaceuticals. (2022). DUPIXENT sales data.
[2] Sanofi. (2023). Pipeline and regulatory updates.
[3] IQVIA. (2022). Biologic drug market analysis.
[4] FDA. (2023). DUPIXENT approvals and indications.
[5] Reuters. (2022). Biologics patent expiration timelines.